Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension.

Competing Interests: Conflict of interest: K.M. Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, Ferrer, GSK, Janssen, MSD, Pfizer and United Therapeutics. J. Fuge has received personal fees/speaker honoraria from AstraZeneca, outside the submitted work. D-H. Park is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1). J.C. Kamp is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1). T. Brod has no disclosures. B. Harrigfeld has no disclosures. J.C. Schupp has patents on new therapies in pulmonary fibrosis and has received lecture fees from Boehringer Ingelheim. M.M. Hoeper reports fees for lectures and/or consultations from Acceleron, Actelion, Altavant, AOP Health, Bayer, Ferrer, Janssen and MSD, and has a patent application filed by MSD for US patent application number 63466014, entitled “Methods of improving lung diffusion capacity in a patient with pulmonary arterial hypertension”.